DCC-2618 | KIT inhibitor | Probechem Biochemicals

Chemical Structure : DCC-2618

CAS No.: 1442472-39-0

DCC-2618 (Ripretinib, DCC2618)

Catalog No.: PC-62101Not For Human Use, Lab Use Only.

DCC-2618 (Ripretinib) is a potent, oral inhibitor of singly and doubly mutated KIT with IC50 of WT (IC50=4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM), D816V.

Packing	Price	Stock
5 mg	$138	In stock
10 mg	$228	In stock
25 mg	$388	In stock
50 mg	$598	In stock
100 mg		Get quote

Get Quotation Now

* Please select Quantity before adding items.

or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Biological Activity

DCC-2618 (Ripretinib, DCC2618) is a potent, oral inhibitor of singly and doubly mutated KIT with IC50 of WT (IC50=4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM), D816V.
DCC-2618 also inhibits PDGFRα/β, KDR and cFMS, robustly inhibits exon 17, exon 9/13, exon 9/14, and exon 9/17 KIT mutants, as well as exon 11/17 KIT mutants.
DCC-2618 inhibits wild type and mutant KIT phosphorylation in cancer cells, demonstrates the potential to treat KIT mutant-driven cancers including GIST, systemic mastocytosis, AML, or melanoma.

Physicochemical Properties

M.Wt	510.367
Formula	C24H21BrFN5O2
Appearance	Solid
CAS No.
Storage	Solide Powder -20 °C 12 Months; 4°C 6 Months	In Solvent -80 °C 6 Months; -20°C 6 Months
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

References

1. Mathias A Schneeweiss, et al. Blood 2016 128:1965.

2. Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.

DCC-2618 (Ripretinib, DCC2618)

Biological Activity

Physicochemical Properties

References

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

Get Quote

* Indicates a Required FieldYour information is safe with us.